Questões de Concurso
Comentadas para analista de planejamento e orçamento
Foram encontradas 672 questões
Resolva questões gratuitamente!
Junte-se a mais de 4 milhões de concurseiros!
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487998
Direito Administrativo
A respeito da descentralização administrativa, da administração pública direta, dos serviços públicos e dos agentes públicos, julgue o item a seguir.
O princípio da modicidade determina que o Estado preste
seus serviços públicos com a maior eficiência possível.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487990
Direito Civil
Com relação à legitimação pelo procedimento e à interpretação no direito, ao nexo entre orçamento e políticas públicas e ao estado de bem-estar social no Brasil, julgue o seguinte item.
Os novos métodos de interpretação jurídica de modo algum
afastam a aplicabilidade dos métodos tradicionais, que
podem ser úteis na aplicação das normas.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487986
Espanhol
Texto associado
El Bellas Artes se renueva
Mientras se acaba de lanzar oficialmente la licitación para
remodelar el Museo Nacional de Bellas Artes y añadir un paseo
de esculturas, avanza el proyecto de mudar el 80% de las reservas
de la institución a un nuevo espacio en Tecnópolis, ya construido,
que albergará parte de las 13 mil obras de ese patrimonio, a tono
con una tendencia internacional de abrir la trastienda de los
museos a todo el público. Con un presupuesto de 840 millones de
pesos, el pliego de la licitación supone un avance concreto en la
remodelación del edificio que recibe 2.000 visitantes por día.
“Es un viejo anhelo el de ampliar el museo y modernizarlo
con ascensores nuevos y circulaciones modernas”, dijo su
director, Andrés Duprat. El hall de circulación estará ubicado en
lo que será el esperado Paseo de Esculturas. Este paseo abrirá de
día y cerrará durante la noche, y a él se podrá acceder también
desde los parques aledaños.
“El proyecto es llevar el 80 por ciento de las reservas a un
edificio nuevo, industrial, que está en Tecnópolis – a 15 minutos
por autopista – donde las obras, que actualmente están en el
subsuelo, van a estar en mejores condiciones ya que es un
espacio tecnologizado, que tendrá aire acondicionado, espacio
adecuado, áreas de trabajo, laboratorio, y sobre todo, la
posibilidad de que el público acceda a verlo”, anticipa Duprat.
Internet:<infobae.com> (con adaptaciones).
Llevando en consideración la información y el vocabulario presentado en el texto, juzgue lo siguiente ítem.
Es posible sustituir “trastienda”, en “a tono con una
tendencia internacional de abrir la trastienda de los museos a
todo el público” (primer párrafo) por carpa, sin que ello
suponga ningún cambio semántico ni gramatical en el texto.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487985
Espanhol
Texto associado
El Bellas Artes se renueva
Mientras se acaba de lanzar oficialmente la licitación para
remodelar el Museo Nacional de Bellas Artes y añadir un paseo
de esculturas, avanza el proyecto de mudar el 80% de las reservas
de la institución a un nuevo espacio en Tecnópolis, ya construido,
que albergará parte de las 13 mil obras de ese patrimonio, a tono
con una tendencia internacional de abrir la trastienda de los
museos a todo el público. Con un presupuesto de 840 millones de
pesos, el pliego de la licitación supone un avance concreto en la
remodelación del edificio que recibe 2.000 visitantes por día.
“Es un viejo anhelo el de ampliar el museo y modernizarlo
con ascensores nuevos y circulaciones modernas”, dijo su
director, Andrés Duprat. El hall de circulación estará ubicado en
lo que será el esperado Paseo de Esculturas. Este paseo abrirá de
día y cerrará durante la noche, y a él se podrá acceder también
desde los parques aledaños.
“El proyecto es llevar el 80 por ciento de las reservas a un
edificio nuevo, industrial, que está en Tecnópolis – a 15 minutos
por autopista – donde las obras, que actualmente están en el
subsuelo, van a estar en mejores condiciones ya que es un
espacio tecnologizado, que tendrá aire acondicionado, espacio
adecuado, áreas de trabajo, laboratorio, y sobre todo, la
posibilidad de que el público acceda a verlo”, anticipa Duprat.
Internet:<infobae.com> (con adaptaciones).
Llevando en consideración la información y el vocabulario presentado en el texto, juzgue lo siguiente ítem.
Si deseásemos recorrer a pie la distancia entre el Museo de
Bellas Artes y el nuevo espacio en Tecnópolis, tardaríamos
aproximadamente un cuarto de hora.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487984
Espanhol
Texto associado
El Bellas Artes se renueva
Mientras se acaba de lanzar oficialmente la licitación para
remodelar el Museo Nacional de Bellas Artes y añadir un paseo
de esculturas, avanza el proyecto de mudar el 80% de las reservas
de la institución a un nuevo espacio en Tecnópolis, ya construido,
que albergará parte de las 13 mil obras de ese patrimonio, a tono
con una tendencia internacional de abrir la trastienda de los
museos a todo el público. Con un presupuesto de 840 millones de
pesos, el pliego de la licitación supone un avance concreto en la
remodelación del edificio que recibe 2.000 visitantes por día.
“Es un viejo anhelo el de ampliar el museo y modernizarlo
con ascensores nuevos y circulaciones modernas”, dijo su
director, Andrés Duprat. El hall de circulación estará ubicado en
lo que será el esperado Paseo de Esculturas. Este paseo abrirá de
día y cerrará durante la noche, y a él se podrá acceder también
desde los parques aledaños.
“El proyecto es llevar el 80 por ciento de las reservas a un
edificio nuevo, industrial, que está en Tecnópolis – a 15 minutos
por autopista – donde las obras, que actualmente están en el
subsuelo, van a estar en mejores condiciones ya que es un
espacio tecnologizado, que tendrá aire acondicionado, espacio
adecuado, áreas de trabajo, laboratorio, y sobre todo, la
posibilidad de que el público acceda a verlo”, anticipa Duprat.
Internet:<infobae.com> (con adaptaciones).
Llevando en consideración la información y el vocabulario presentado en el texto, juzgue lo siguiente ítem.
Los visitantes diarios del Museo Nacional de Bellas Artes
generan un montante de 840 millones de pesos, cantidad que
podrá ser utilizada en su reforma.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487983
Espanhol
Texto associado
El Bellas Artes se renueva
Mientras se acaba de lanzar oficialmente la licitación para
remodelar el Museo Nacional de Bellas Artes y añadir un paseo
de esculturas, avanza el proyecto de mudar el 80% de las reservas
de la institución a un nuevo espacio en Tecnópolis, ya construido,
que albergará parte de las 13 mil obras de ese patrimonio, a tono
con una tendencia internacional de abrir la trastienda de los
museos a todo el público. Con un presupuesto de 840 millones de
pesos, el pliego de la licitación supone un avance concreto en la
remodelación del edificio que recibe 2.000 visitantes por día.
“Es un viejo anhelo el de ampliar el museo y modernizarlo
con ascensores nuevos y circulaciones modernas”, dijo su
director, Andrés Duprat. El hall de circulación estará ubicado en
lo que será el esperado Paseo de Esculturas. Este paseo abrirá de
día y cerrará durante la noche, y a él se podrá acceder también
desde los parques aledaños.
“El proyecto es llevar el 80 por ciento de las reservas a un
edificio nuevo, industrial, que está en Tecnópolis – a 15 minutos
por autopista – donde las obras, que actualmente están en el
subsuelo, van a estar en mejores condiciones ya que es un
espacio tecnologizado, que tendrá aire acondicionado, espacio
adecuado, áreas de trabajo, laboratorio, y sobre todo, la
posibilidad de que el público acceda a verlo”, anticipa Duprat.
Internet:<infobae.com> (con adaptaciones).
Llevando en consideración la información y el vocabulario presentado en el texto, juzgue lo siguiente ítem.
La reforma del Museo Nacional de Bellas Artes está de
acorde con una tendencia mundial de facilitar el acceso al
acervo que, anteriormente, permanecía indisponible para
visitación.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487982
Espanhol
Texto associado
El Bellas Artes se renueva
Mientras se acaba de lanzar oficialmente la licitación para
remodelar el Museo Nacional de Bellas Artes y añadir un paseo
de esculturas, avanza el proyecto de mudar el 80% de las reservas
de la institución a un nuevo espacio en Tecnópolis, ya construido,
que albergará parte de las 13 mil obras de ese patrimonio, a tono
con una tendencia internacional de abrir la trastienda de los
museos a todo el público. Con un presupuesto de 840 millones de
pesos, el pliego de la licitación supone un avance concreto en la
remodelación del edificio que recibe 2.000 visitantes por día.
“Es un viejo anhelo el de ampliar el museo y modernizarlo
con ascensores nuevos y circulaciones modernas”, dijo su
director, Andrés Duprat. El hall de circulación estará ubicado en
lo que será el esperado Paseo de Esculturas. Este paseo abrirá de
día y cerrará durante la noche, y a él se podrá acceder también
desde los parques aledaños.
“El proyecto es llevar el 80 por ciento de las reservas a un
edificio nuevo, industrial, que está en Tecnópolis – a 15 minutos
por autopista – donde las obras, que actualmente están en el
subsuelo, van a estar en mejores condiciones ya que es un
espacio tecnologizado, que tendrá aire acondicionado, espacio
adecuado, áreas de trabajo, laboratorio, y sobre todo, la
posibilidad de que el público acceda a verlo”, anticipa Duprat.
Internet:<infobae.com> (con adaptaciones).
Llevando en consideración la información y el vocabulario presentado en el texto, juzgue lo siguiente ítem.
Una vez reformado el Museo de Bellas Artes, será posible
acceder al Paseo de Esculturas por distintos sitios.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487980
Inglês
Texto associado
The Scottish government’s forestry agency is aiming to
grow and nurture millions of saplings indoors before transferring
them to the wild. It’s not alone in its ambition to re-green its
land; countries, companies, and non-profits around the world
have been pledging to plant millions or even billions of trees as a
way to combat climate change. Ethiopia set a record when it
planted an estimated 350 million trees in one day in 2019.
When it comes to planting trees, though, simply scattering
millions of seeds isn’t going to do the trick, as there are all sorts
of factors that can prevent a seed from germinating and growing
into a full-fledged tree. Hence the strategy Forestry and
Land Scotland (FLS) wants to use: plant saplings, not seeds, and
crank those saplings out faster than nature could. In the wild, it
would take about 18 months to grow a tree seedling 40 to
50 millimeters, while in a vertical farm it can take as little as
90 days.
Not just any vertical farm, though. The technology for the
FLS initiative is coming from an Edinburgh-based company
called Intelligent Growth Solutions (IGS), which makes modular,
scalable vertical farming systems it calls Growth Towers. FLS
has grown several batches of vertically-farmed saplings as a
proof of concept, which are now maturing in open-air nurseries
before being transferred to their permanent home in the
Scottish Highlands.
In 2019 the United Kingdom (UK) government pledged to
plant 30,000 hectares (115.8 square miles) of new forests by the
end of 2024, but they’re looking unlikely to meet that target.
Nevertheless, after thousands of years of decimating forests, it’s
now possible for us to become the first generation of humans that
expands them. However, it’s going to take some serious
strategizing, dedication, and technology; and it seems vertical
farming could be a valuable ingredient in the recipe for global
re-forestation.
Internet:<singularityhub.com>(adapted).
According to the previous text, judge the following item.
Dispersing seeds is enough to avoid the issues related to the
process of becoming a completely developed tree.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487979
Inglês
Texto associado
The Scottish government’s forestry agency is aiming to
grow and nurture millions of saplings indoors before transferring
them to the wild. It’s not alone in its ambition to re-green its
land; countries, companies, and non-profits around the world
have been pledging to plant millions or even billions of trees as a
way to combat climate change. Ethiopia set a record when it
planted an estimated 350 million trees in one day in 2019.
When it comes to planting trees, though, simply scattering
millions of seeds isn’t going to do the trick, as there are all sorts
of factors that can prevent a seed from germinating and growing
into a full-fledged tree. Hence the strategy Forestry and
Land Scotland (FLS) wants to use: plant saplings, not seeds, and
crank those saplings out faster than nature could. In the wild, it
would take about 18 months to grow a tree seedling 40 to
50 millimeters, while in a vertical farm it can take as little as
90 days.
Not just any vertical farm, though. The technology for the
FLS initiative is coming from an Edinburgh-based company
called Intelligent Growth Solutions (IGS), which makes modular,
scalable vertical farming systems it calls Growth Towers. FLS
has grown several batches of vertically-farmed saplings as a
proof of concept, which are now maturing in open-air nurseries
before being transferred to their permanent home in the
Scottish Highlands.
In 2019 the United Kingdom (UK) government pledged to
plant 30,000 hectares (115.8 square miles) of new forests by the
end of 2024, but they’re looking unlikely to meet that target.
Nevertheless, after thousands of years of decimating forests, it’s
now possible for us to become the first generation of humans that
expands them. However, it’s going to take some serious
strategizing, dedication, and technology; and it seems vertical
farming could be a valuable ingredient in the recipe for global
re-forestation.
Internet:<singularityhub.com>(adapted).
According to the previous text, judge the following item.
The process put in place by FLS prepares the saplings to be
planted in permanent soil straight after their growth in the
vertical farms.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487978
Inglês
Texto associado
The Scottish government’s forestry agency is aiming to
grow and nurture millions of saplings indoors before transferring
them to the wild. It’s not alone in its ambition to re-green its
land; countries, companies, and non-profits around the world
have been pledging to plant millions or even billions of trees as a
way to combat climate change. Ethiopia set a record when it
planted an estimated 350 million trees in one day in 2019.
When it comes to planting trees, though, simply scattering
millions of seeds isn’t going to do the trick, as there are all sorts
of factors that can prevent a seed from germinating and growing
into a full-fledged tree. Hence the strategy Forestry and
Land Scotland (FLS) wants to use: plant saplings, not seeds, and
crank those saplings out faster than nature could. In the wild, it
would take about 18 months to grow a tree seedling 40 to
50 millimeters, while in a vertical farm it can take as little as
90 days.
Not just any vertical farm, though. The technology for the
FLS initiative is coming from an Edinburgh-based company
called Intelligent Growth Solutions (IGS), which makes modular,
scalable vertical farming systems it calls Growth Towers. FLS
has grown several batches of vertically-farmed saplings as a
proof of concept, which are now maturing in open-air nurseries
before being transferred to their permanent home in the
Scottish Highlands.
In 2019 the United Kingdom (UK) government pledged to
plant 30,000 hectares (115.8 square miles) of new forests by the
end of 2024, but they’re looking unlikely to meet that target.
Nevertheless, after thousands of years of decimating forests, it’s
now possible for us to become the first generation of humans that
expands them. However, it’s going to take some serious
strategizing, dedication, and technology; and it seems vertical
farming could be a valuable ingredient in the recipe for global
re-forestation.
Internet:<singularityhub.com>(adapted).
According to the previous text, judge the following item.
Ethiopia has set a precedent in the use of indoor technology
to plant and grow trees.
Ano: 2024
Banca:
CESPE / CEBRASPE
Órgão:
MPO
Prova:
CESPE / CEBRASPE - 2024 - MPO - Conhecimentos gerais para todas as especialidades |
Q2487977
Inglês
Texto associado
The Scottish government’s forestry agency is aiming to
grow and nurture millions of saplings indoors before transferring
them to the wild. It’s not alone in its ambition to re-green its
land; countries, companies, and non-profits around the world
have been pledging to plant millions or even billions of trees as a
way to combat climate change. Ethiopia set a record when it
planted an estimated 350 million trees in one day in 2019.
When it comes to planting trees, though, simply scattering
millions of seeds isn’t going to do the trick, as there are all sorts
of factors that can prevent a seed from germinating and growing
into a full-fledged tree. Hence the strategy Forestry and
Land Scotland (FLS) wants to use: plant saplings, not seeds, and
crank those saplings out faster than nature could. In the wild, it
would take about 18 months to grow a tree seedling 40 to
50 millimeters, while in a vertical farm it can take as little as
90 days.
Not just any vertical farm, though. The technology for the
FLS initiative is coming from an Edinburgh-based company
called Intelligent Growth Solutions (IGS), which makes modular,
scalable vertical farming systems it calls Growth Towers. FLS
has grown several batches of vertically-farmed saplings as a
proof of concept, which are now maturing in open-air nurseries
before being transferred to their permanent home in the
Scottish Highlands.
In 2019 the United Kingdom (UK) government pledged to
plant 30,000 hectares (115.8 square miles) of new forests by the
end of 2024, but they’re looking unlikely to meet that target.
Nevertheless, after thousands of years of decimating forests, it’s
now possible for us to become the first generation of humans that
expands them. However, it’s going to take some serious
strategizing, dedication, and technology; and it seems vertical
farming could be a valuable ingredient in the recipe for global
re-forestation.
Internet:<singularityhub.com>(adapted).
According to the previous text, judge the following item.
Even if the UK government’s re-forestation goal cannot be
reached, the prospect of renewed forested area is on the
horizon.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242138
Inglês
Texto associado
The hard cell
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and
ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next
year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Instruções: Para responder a questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242137
Inglês
Texto associado
The hard cell
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and
ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next
year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Instruções: Para responder a questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242136
Inglês
Texto associado
The hard cell
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and
ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next
year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Instruções: Para responder a questão,
assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a
lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242133
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the
Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are
characterized by underpricing. Most of the theoretical literature
has linked the size of underpricing to the IPO procedure used on
the primary market. In this paper, by using a matched sample of
NYSE and Nasdaq IPOs, we show that the size of underpricing
also depends on the trading method used in the IPO
aftermarket.
There are two major methods of opening trading of initial
public offerings (IPOs) in the U.S. The NYSE is an order-driven
market ....56... a call auction allows supply and demand to be
aggregated (at one location) prior to the start of trading. .....57.... ,
Nasdaq is a quote-driven market. Dealers can only specify their
best quotes, and participants have KK
58 idea of supply and
demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm
value and test it. Our results show that there is a larger level of
uncertainty at the beginning of trading on Nasdaq than on the
NYSE. This in turn is associated with larger levels of
underpricing for Nasdaq IPOs. We suggest that this may be due
to the different informational efficiency of the two trading
systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão, assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242132
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the
Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are
characterized by underpricing. Most of the theoretical literature
has linked the size of underpricing to the IPO procedure used on
the primary market. In this paper, by using a matched sample of
NYSE and Nasdaq IPOs, we show that the size of underpricing
also depends on the trading method used in the IPO
aftermarket.
There are two major methods of opening trading of initial
public offerings (IPOs) in the U.S. The NYSE is an order-driven
market ....56... a call auction allows supply and demand to be
aggregated (at one location) prior to the start of trading. .....57.... ,
Nasdaq is a quote-driven market. Dealers can only specify their
best quotes, and participants have KK
58 idea of supply and
demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm
value and test it. Our results show that there is a larger level of
uncertainty at the beginning of trading on Nasdaq than on the
NYSE. This in turn is associated with larger levels of
underpricing for Nasdaq IPOs. We suggest that this may be due
to the different informational efficiency of the two trading
systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão, assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242131
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the
Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are
characterized by underpricing. Most of the theoretical literature
has linked the size of underpricing to the IPO procedure used on
the primary market. In this paper, by using a matched sample of
NYSE and Nasdaq IPOs, we show that the size of underpricing
also depends on the trading method used in the IPO
aftermarket.
There are two major methods of opening trading of initial
public offerings (IPOs) in the U.S. The NYSE is an order-driven
market ....56... a call auction allows supply and demand to be
aggregated (at one location) prior to the start of trading. .....57.... ,
Nasdaq is a quote-driven market. Dealers can only specify their
best quotes, and participants have KK
58 idea of supply and
demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm
value and test it. Our results show that there is a larger level of
uncertainty at the beginning of trading on Nasdaq than on the
NYSE. This in turn is associated with larger levels of
underpricing for Nasdaq IPOs. We suggest that this may be due
to the different informational efficiency of the two trading
systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão,
assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242095
Direito Administrativo
O significado dos seguintes instrumentos administrativos
da Administração Pública, em diferentes níveis, são:
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242094
Direito Administrativo
Há, na Administração Pública brasileira, servidores que
possuem um estatuto jurídico distinto dos demais servidores, caso específico do chamado “regime especial”. O
“regime especial” pode ser aplicado, dentre outras situações excepcionais,
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242092
Direito Administrativo
A terminologia funcional contém em si um ordenamento
jurídico próprio, fundamental ao Estado e à Administração
Pública. Assim, "cargo público" é o conjunto de atribuições
e responsabilidades
Conheça nossos planos